Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 214

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 214
---
in. If the General Meeting approves this change in governance and the proposed composition of the Board of Directors, the Board of Directors is expected to appoint Irina Staatz-Granzer as its Chairwoman and Jonathan Dickinson as Chief Executive Officer at its first meeting after the General Meeting.

If shareholders do not approve the governance change, it would be proposed to renew the mandate of the current members of the Supervisory Board whose terms of office are due to expire - with the exception of Gilles Brisson and Jean-Yves Blay - and to appoint two new members, Marty J. Duvall and Christian Itin. The composition of the Executive Board would remain unchanged, as Jonathan Dickinson would remain Chairman and Yannis Morel and Sonia Quaratino would remain members (Arvind Sood resigned from his position on the Executive Board in February 2025).

Mr. Marty J. Duvall is a biotechnology executive based in the United States, with over 35 years of experience building companies in the pharmaceutical and biotechnology industry, focused in specialty therapeutics. Mr. Duvall’s main pharma experience includes global oncology leadership positions at Aventis and Merck. His biotech experience includes leading to strategic transactions at MGI Pharma, Abraxis Bioscience, and ARIAD, where he worked to build a footprint across the United States, Europe and Asia. His chief executive officer experience includes public companies (Tocagen and Oncopeptides) as well as private companies (Angiex). With an oncology focus over the last three decades, Mr. Duvall has helped launch and drive therapeutics for patients with a range of cancers.

Dr Christian Itin is a biotechnology company leader with more than 25 years of industry experience. He currently serves as CEO of Autolus Therapeutics. Previously, Mr. Itin was President and Chief Executive Officer of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company acquired in March 2012 by Amgen, Inc. Micromet developed the first T-cell engaging antibody Blincyto®. From 2016 to 2019, Mr. Itin was on the board of Kuros Biosciences serving as chairman from 2016 to 2018. Prior to Kuros he served as executive chairman of Cytos Biotechnology Ltd from 2012 to 2016 until its merger with Kuros Biosurgery, forming Kuros Biosciences. Kuros developed and is commercializing MagnetOS™, a